Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents from an early-stage precision-oncology firm can feel like lab notebooks—dense trial statistics, genomic jargon, and hidden R&D costs. Tango Therapeutics (TNGX) adds extra layers with CRISPR screening expenses, PRMT5 milestones, and USP1 safety data. If you have ever searched “where can I read Tango Therapeutics’ quarterly earnings report 10-Q filing” or “Tango Therapeutics insider trading Form 4 transactions,” you know how difficult it is to unearth the specifics that move a biotech stock.
Stock Titan solves that problem. Our AI ingests every disclosure the moment it hits EDGAR and translates it into plain English. Need “Tango Therapeutics Form 4 insider transactions real-time”? Alerts arrive seconds after each executive trade. Want liquidity details? We highlight cash-burn figures inside the 10-Q. Think of it as “Tango Therapeutics SEC filings explained simply” — machine-generated summaries vetted by finance professionals. For anyone Googling “understanding Tango Therapeutics SEC documents with AI,” this is your starting point.
Filings matter because Tango’s value swings on clinical catalysts. Our dashboard flags first-in-human dosing dates from 8-Ks—literally “Tango Therapeutics 8-K material events explained.” It extracts compensation tables from the “Tango Therapeutics proxy statement executive compensation,” and tracks every “Tango Therapeutics executive stock transactions Form 4.” Leverage our “Tango Therapeutics earnings report filing analysis” to gauge dilution risk, or open the “Tango Therapeutics annual report 10-K simplified” module for a crisp view of pipeline timelines. With AI-powered summaries, real-time updates, and complete coverage of every form, Stock Titan turns complex science into clear, actionable insight.
Tango Therapeutics, Inc. entered into a new Sales Agreement with Leerink Partners LLC, establishing an at-the-market equity program under which it may sell up to $100,000,000 of its common stock from time to time. Shares may be sold through Leerink as sales agent in transactions deemed an “at the market offering” or in negotiated deals if authorized by the company. Tango will pay the agent a commission of up to 3.0% of the gross sales price of any shares sold and has provided customary indemnification rights.
The company also terminated its prior Open Market Sales Agreement with Jefferies LLC, under which it had similarly been able to sell up to $100,000,000 of common stock. The Jefferies agreement ends effective November 21, 2025, and Tango states it will not face termination penalties and will no longer offer or sell shares under the 2022 ATM program.
Tango Therapeutics, Inc. has filed a resale registration covering up to 1,732,101 shares of its common stock, all to be sold from time to time by a single selling stockholder. These shares were already issued in an October 2025 private placement at $8.66 per share, which provided Tango with $15 million in gross proceeds; the company will receive no cash from any future resales under this prospectus.
Tango is an oncology company developing targeted therapies against tumor suppressor gene loss. Lead program vopimetostat (TNG462) showed a 27% objective response rate and 6.4‑month median progression‑free survival across 94 tumor‑evaluable patients with MTAP‑deleted cancers, including a 25% response rate in second‑line pancreatic cancer and 49% in a histology‑selective cohort. Additional pipeline assets include brain‑penetrant PRMT5 inhibitor TNG456, CoREST inhibitor TNG260, and HBS1L degrader TNG961.
Tango Therapeutics (TNGX) reported a director’s Form 4 reflecting a grant of stock options for 150,000 shares at an exercise price of $8.01 on November 3, 2025.
The options expire on November 3, 2035 and vest in 48 substantially equal monthly installments over four years, with the first vesting date on December 3, 2025, subject to continuous service. After this transaction, the reporting person directly holds 150,000 derivative securities.
Tango Therapeutics (TNGX) furnished a press release covering its results of operations and financial condition for the quarter ended September 30, 2025, via an Item 2.02 Form 8‑K.
The press release is furnished, not filed, and appears as Exhibit 99.1. The report was signed by Chief Financial Officer Daniella Beckman.
Tango Therapeutics (TNGX) reported a profitable Q3 on collaboration revenue tied to its Gilead partnership. Total revenue was $53.811 million, primarily from recognizing $53.8 million after the research term was mutually truncated, leading to operating income of $14.1 million and net income of $15.9 million (diluted EPS $0.13). By comparison, Q3 2024 revenue was $11.607 million with a net loss.
Year-to-date, revenue reached $62.384 million, with a net loss of $62.845 million reflecting R&D and G&A spend as development continues. Cash, cash equivalents and marketable securities were $152.8 million as of September 30, 2025. In October, the company closed an underwritten offering and concurrent private placement for $212.0 million in net proceeds, and expects a cash runway into 2028.
Pipeline updates include vopimetostat (PRMT5 inhibitor) with encouraging Phase 1/2 data: across 94 tumor-evaluable MTAP-deleted patients, ORR was 27% and mPFS 6.4 months; in second-line pancreatic cancer, mPFS was 7.2 months and ORR 25% (n=8), supporting a planned pivotal study. A histology-selective cohort showed ORR 49% and mPFS 9.1 months. TNG456 began dose escalation in GBM-focused MTAP-deleted tumors, and TNG260 reached an 80 mg QD MTD with early signals in a defined NSCLC subset.
Tango Therapeutics (TNGX): Third Rock Ventures IV, L.P. reported an open-market sale of common stock. On 10/23/2025, the reporting person sold 477,401 shares (Transaction Code S) at a weighted average price of $10.152, with individual trades executed between $10.00 and $10.65.
Following the sale, the filing reports 13,386,574 shares beneficially owned. The shares are directly held by Third Rock Ventures IV, L.P.; affiliated general partners are listed and disclaim beneficial ownership except to the extent of any pecuniary interest.
Tango Therapeutics (TNGX) entered an underwriting agreement for a registered direct offering of 21,023,337 common shares and pre-funded warrants exercisable for up to 3,226,458 shares. Each share was sold at $8.66 and each pre-funded warrant at $8.659, with an exercise price of $0.001. All securities were sold by the company.
The company estimates net proceeds of approximately $197 million from the registered direct offering, expected to close on October 24, 2025, and plans to use the funds to advance its pipeline, working capital, and general corporate purposes. Pre-funded warrants are immediately exercisable, do not expire, and include beneficial ownership caps of 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ notice. Tango also agreed to a concurrent $15 million private placement of 1,732,101 shares at $8.66 per share. With these financings and existing cash, the company believes it can fund operations into 2028.
Tango Therapeutics (TNGX) launched a primary offering of 21,023,337 shares of common stock and pre-funded warrants to purchase up to 3,226,458 shares, with the warrant shares also covered by this supplement. The offering is priced at $8.66 per share and $8.659 per pre-funded warrant, for a total offering price of $209,999,998, yielding estimated net proceeds of $197,399,805 before expenses.
In a concurrent private placement, Tango agreed to sell 1,732,101 shares at $8.66 per share; those securities are not registered here, and this offering is not conditioned on the PIPE. The company estimates cash, cash equivalents and marketable securities of approximately $152.8 million as of September 30, 2025. Tango intends to use proceeds to advance its pipeline and for general corporate purposes, stating that the combined funds are expected to support operations into 2028. The underwriter expects to deliver the securities on or about October 24, 2025.
Tango Therapeutics (TNGX) filed an 8‑K disclosing preliminary liquidity and a clinical update. As of September 30, 2025, the company estimates it had $152.8 million in cash, cash equivalents and marketable securities. Management emphasized this figure is preliminary and unaudited and may change after quarter‑end closing procedures.
The company also made available a slide presentation with a clinical update from its ongoing Phase 1/2 trial of vopimetostat (formerly TNG462), furnished as Exhibit 99.1. The external auditor has not performed any review or assurance procedures on the preliminary data.
Third Rock Ventures IV, L.P. reported a sale of 500,000 shares of Tango Therapeutics, Inc. (TNGX) executed on 09/25/2025 at a weighted-average price of $8.017 per share. After the sale, the reporting person holds 13,863,975 shares, which are directly held by Third Rock Ventures IV, L.P. The filing identifies Third Rock Ventures GP IV, L.P. and TRV GP IV, LLC as related entities that disclaim beneficial ownership except to the extent of any pecuniary interest. The form was signed by Kevin Gillis on 09/29/2025.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
